Pfizer’s Selzentry Wins FDA Approval For HIV

First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet